Patent · US Active

Tumour necrosis factor receptor fusion proteins and methods of using the same

US9731007B2 · kind B2 · utility

1Cited by

0References

14Claims

0Family size

Assignee

NEXVET AUSTRALIA PTY LTD · AU

Inventors

Alexander Drew · Sydney, AU
David Gearing · Melbourne, AU

Key dates

Filing date	Feb 22, 2013
Grant date	Aug 15, 2017
Priority date	—
Expiry date	Oct 11, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A chimeric fusion polypeptide is provided comprising an extracellular domain of a canine TNF receptor p60 or p80 polypeptide conjoined to an Fc region of a canine IgG immunoglobulin heavy chain. The chimeric fusion polypeptide may be used in the treatment or prevention of conditions in canines mediated by TNF expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.